Progress in Clinical Trials of Tumor Immunodrugs in the United States

Malignant tumors are a key factor that threatens human health. With the continuous development of molecular biology, immunology and oncology, tumor immunodrugs have gradually become an effective means to suppress malignant tumors after surgery, radiotherapy and chemotherapy. The United States, as a leading country in the development of tumor immunodrugs, has rich clinical trial practice experience and comprehensive clinical trial considerations. Therefore, this article intends to explore the progress of clinical trials of tumor immunodrugs in the United States in terms of the alternative endpoints of clinical trials, clinical trials of adolescent tumor patients, and the design of a single clinical trial main plan for multiple drugs and/or multiple tumor subgroups, thereby providing a reference for optimizing the design of clinical trials in China, expanding the application scope of tumor immunodrugs, and speeding up the process of marketing new drugs.